Vaccine immunotherapy
AssigneeIRX Therapeutics, Inc.
InventorsJohn W. Hadden, Kathy Signorelli, James Egan, Paul Naylor
Life of this patent
Estimating the term…
Loading patent…
AssigneeIRX Therapeutics, Inc.
InventorsJohn W. Hadden, Kathy Signorelli, James Egan, Paul Naylor
Estimating the term…
A composition for treating cancer, including synergistic amounts of a primary cell-derived biologic having the cytokines IL-1, IL-2, IL-6, IL-8, TNF-α, and IFN-γ, and a cancer vaccine having at least one antigen. A composition comprising synergistic amounts of the primary cell-derived biologic in combination with at least one adjuvant. A method of treating cancer by administering the composition. A method of reversing immune suppression and gaining immunity to cancer. A method of producing an immune response to an exogenous antigen. A method of enhancing an immune response in a patient by administering the primary cell-derived biologic in combination with at least one adjuvant, and enhancing the immune response of the patient by a synergistic interaction of the primary cell-derived biologic and the adjuvant. A method of increasing function of an immune system.
A composition for enhancing an immune response in a patient, comprising:
A method of enhancing an immune response in a patient, comprising administering to the patient:
Dependencies are inferred from the claim text.